혈관 폐쇄 장치 시장 : 제품 유형, 시술 유형, 액세스 부위, 최종 사용자, 유통 채널별 예측(2026-2032년)

The Vascular Closure Device Market is projected to grow by USD 3.11 billion at a CAGR of 7.71% by 2032.

Vascular Closure Device Market Introduction

The vascular closure device market is expanding as hospitals seek faster, safer hemostasis after catheter-based cardiovascular, peripheral vascular, and structural heart procedures. These devices close arterial access sites after femoral and other vascular punctures, reducing time to hemostasis and ambulation compared with prolonged manual compression in appropriately selected patients.

Demand is supported by the global cardiovascular disease burden: the World Health Organization identifies cardiovascular disease as the leading cause of death worldwide, responsible for an estimated 17.9 million deaths in 2019. Adoption is also tied to minimally invasive interventions, aging populations, day-case catheterization pathways, and continued use of femoral access for large-bore procedures such as transcatheter aortic valve replacement, endovascular aneurysm repair, and mechanical circulatory support.

Transformative Shifts in the Vascular Closure Landscape

The vascular closure device landscape is being reshaped by access-site strategy, procedural complexity, and hospital efficiency goals. Radial access has reduced femoral use in many coronary interventions because clinical evidence and professional guidelines associate radial percutaneous coronary intervention with fewer bleeding and vascular complications in suitable patients. However, femoral artery closure remains essential for large-bore and complex procedures where radial access is not feasible.

Technology development is advancing across suture-mediated, collagen-based, clip-based, plug-based, and resorbable closure systems designed for predictable hemostasis, lower complication risk, and compatibility with larger sheath sizes. Hospitals are also standardizing ultrasound-guided access, anticoagulation protocols, and same-day discharge workflows, making device reliability, clinical evidence, and operator training central purchasing criteria.

Cumulative Impact of Artificial Intelligence on Closure Devices

Artificial intelligence is beginning to influence the vascular closure device market through the broader interventional care pathway rather than through closure alone. The U.S. Food and Drug Administration's public list of AI/ML-enabled medical devices has expanded rapidly, demonstrating accelerating clinical adoption of artificial intelligence in imaging, diagnostics, workflow optimization, and procedural support.

In vascular access management, AI can support pre-procedure risk stratification, vessel assessment from ultrasound or CT imaging, prediction of bleeding and access-site complications, and post-procedure surveillance. For suppliers, AI-enabled analytics can improve inventory planning, complaint trending, training effectiveness, quality systems, and real-world evidence generation. Adoption must remain clinically validated, transparent, and aligned with data privacy and medical device regulatory requirements.

Key Regional Insights Across Global Vascular Closure Demand

North America remains a high-value region for vascular closure devices due to advanced catheterization laboratory infrastructure, strong adoption of percutaneous coronary intervention, transcatheter aortic valve replacement, peripheral interventions, and established regulatory pathways through the U.S. Food and Drug Administration and Health Canada. Europe is shaped by mature interventional cardiology networks and the EU Medical Device Regulation, which raises expectations for clinical evidence, post-market surveillance, quality management, and device traceability.

Asia-Pacific is gaining momentum as China, India, Japan, South Korea, and Australia expand cardiovascular procedure capacity, specialist training, and hospital infrastructure. Latin America, led by Brazil and Mexico, shows steady demand for femoral artery closure and hemostasis management, although reimbursement, procurement, and access remain uneven across public and private systems. The Middle East is investing in specialty cardiac centers, particularly in Gulf economies with national health transformation programs, while Africa remains earlier-stage, with adoption tied to catheterization laboratory availability, clinician training, public-private investment, and broader access to interventional cardiovascular care.

Key Group Insights for Market Prioritization

ASEAN markets are benefiting from cardiovascular infrastructure investment, medical tourism, and growing private hospital networks, although procurement remains fragmented by country and varies with reimbursement maturity. GCC demand is supported by national health transformation programs, high cardiometabolic disease prevalence documented by regional public health authorities, and investment in tertiary cardiac care, making reliable vascular access closure important for efficient cath lab throughput.

The European Union creates a harmonized but more demanding compliance environment under the Medical Device Regulation, favoring suppliers with strong clinical documentation, post-market clinical follow-up, and quality systems. BRICS markets combine large patient populations, expanding cardiovascular care capacity, and cost sensitivity, making local partnerships, education, and tiered access strategies important. G7 countries remain innovation-led and evidence-driven, while NATO member markets often overlap with advanced hospital systems that increasingly emphasize supply-chain resilience, standardized clinical readiness, and compliant medical device procurement.

Key Country Insights in the Vascular Closure Device Market

The United States is a core market due to high interventional procedure volumes, outpatient migration, broad use of advanced structural heart techniques, and established pathways for medical device clearance and surveillance. Canada emphasizes safety, value, provincial procurement discipline, and clinical evidence. Mexico and Brazil present expanding opportunities through private hospitals, cardiovascular infrastructure development, and improving access to interventional cardiology, while reimbursement variability continues to influence adoption.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established catheterization laboratory networks, evidence-based purchasing, and growing demand for efficient post-procedure recovery. Russia places greater emphasis on localization, regulatory continuity, and supply security. In Asia-Pacific, China and India offer scale and rising cardiovascular procedure volumes, Japan prioritizes quality and safety for an aging population, Australia maintains high clinical and regulatory standards, and South Korea combines advanced technology adoption with strong hospital capabilities and specialist interventional expertise.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinical differentiation supported by real-world evidence, including time to hemostasis, time to ambulation, access-site complication rates, large-bore closure performance, patient selection, and total cost of care. Devices that integrate smoothly with ultrasound-guided access, anticoagulated patients, and same-day discharge protocols are better positioned for hospital adoption.

Suppliers should strengthen physician training, simulation programs, proctoring, and post-market surveillance while tailoring value propositions by region. In mature markets, health economics, regulatory compliance, and FDA- or MDR-quality evidence are decisive. In emerging markets, affordability, distributor quality, local service, and clinical education drive access. AI-enabled analytics should be used to improve quality systems, demand planning, training impact measurement, and outcomes evidence without overstating unvalidated clinical claims.

Research Methodology and Evidence Base

This executive summary applies a secondary research methodology using publicly available and institutionally recognized sources, including the World Health Organization, U.S. Food and Drug Administration, OECD health indicators, national cardiovascular and regulatory agencies, peer-reviewed interventional cardiology literature, clinical guidelines, and medical device regulatory frameworks.

Insights were triangulated across cardiovascular disease burden, procedure trends, access-site practice patterns, reimbursement environment, regulatory requirements, technology adoption, and hospital workflow priorities. The analysis emphasizes verified directional evidence rather than unsupported market sizing claims, ensuring that conclusions on vascular closure devices, femoral artery closure, large-bore closure, and hemostasis management remain defensible for strategic decision-making.

Conclusion: Strategic Outlook for Vascular Closure Devices

The vascular closure device market is positioned for sustained relevance as minimally invasive cardiovascular and endovascular procedures grow worldwide. While radial access has changed coronary practice, femoral and large-bore access continue to require reliable closure solutions that reduce workflow burden, support patient mobility, and help hospitals standardize post-procedure recovery.

Future competitive advantage will depend on clinical evidence, operator training, regulatory excellence, post-market surveillance, and region-specific market access strategies. Organizations that demonstrate measurable safety, efficiency, and economic value will be best placed to meet demand across mature health systems and emerging healthcare markets.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Vascular Closure Device Market, by Product Type

• 7.1. Clip Based Devices
• 7.2. Collagen Plug Devices
  • 7.2.1. Bovine Collagen Plugs
  • 7.2.2. Synthetic Collagen Plugs
• 7.3. External Compression Devices
• 7.4. Sealant Based Devices
  • 7.4.1. Chitosan Sealants
  • 7.4.2. Polyethylene Glycol Sealants
• 7.5. Suture Based Devices

8. Vascular Closure Device Market, by Procedure Type

• 8.1. Diagnostic Procedures
  • 8.1.1. Angiographic Procedures
  • 8.1.2. Hemodynamic Monitoring
• 8.2. Interventional Procedures
  • 8.2.1. Cardiovascular Interventions
  • 8.2.2. Peripheral Vascular Interventions

9. Vascular Closure Device Market, by Access Site

• 9.1. Femoral Access
• 9.2. Radial Access

10. Vascular Closure Device Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Clinics
• 10.3. Hospitals

11. Vascular Closure Device Market, by Distribution Channel

• 11.1. Direct Sales
• 11.2. Third Party Distributors

12. Vascular Closure Device Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Vascular Closure Device Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Vascular Closure Device Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Acandis GmbH
• 16.3. Advanced Vascular Dynamics
• 16.4. AngioDynamics Inc
• 16.5. Asahi Intecc Co Ltd
• 16.6. B Braun Melsungen AG
• 16.7. Biotronik SE & Co KG
• 16.8. Boston Scientific Corporation
• 16.9. Cardinal Health Inc
• 16.10. Cook Medical LLC
• 16.11. Cordis US Corp
• 16.12. Forge Medical Inc
• 16.13. Haemonetics Corporation
• 16.14. Inari Medical Inc
• 16.15. iVascular SLU
• 16.16. Lepu Medical Technology Beijing Co Ltd
• 16.17. Medtronic plc
• 16.18. Meril Life Sciences Pvt Ltd
• 16.19. Merit Medical Systems Inc
• 16.20. Morris Innovative Inc
• 16.21. Rex Medical LP
• 16.22. Teleflex Incorporated
• 16.23. Terumo Corporation
• 16.24. Transluminal Technologies LLC
• 16.25. Tricol Biomedical Inc
• 16.26. TZ Medical Inc
• 16.27. Vasorum Ltd
• 16.28. Vivasure Medical Ltd
• 16.29. W L Gore & Associates Inc